Pentaerithrityl tetranitrate (PETN) is a long-acting donor of nitric oxide (NO) and has recently been characterized as an antianginal agent that, in contrast with other nitric acid esters, does not induce oxidative stress and is therefore free of tolerance. Moreover, animal experiments have revealed that PETN actively reduces oxygen radical formation in vivoand specifically prevents atherogenesis and endothelial dysfunction. Because heme oxygenase-1 (HO-1) has been described as an antiatherogenic and cytoprotective gene in the endothelium, our aim was to investigate the effect of the active PETN metabolite pentaerithrityl trinitrate (PETriN) on HO-1 expression and catalytic activity in endothelial cells. Endothelial cells derived from human umbilical vein were incubated with PETriN (0.01–1 mM) for 8 hr. PETriN increased HO-1 mRNA and protein levels in a concentration-dependent fashion up to 3-fold over basal levels. Elevation of HO-1 protein was accompanied by a marked increase in catalytic activity of the enzyme as reflected by enhanced formation of both carbon monoxide and the endogenous antioxidant, bilirubin. Pretreatment of endothelial cells with PETriN or bilirubin at low micromolar concentrations protected endothelial cells from hydrogen peroxide-mediated toxicity. HO-1 induction and endothelial protection by PETriN were not mimicked by isosorbide dinitrate, another long-acting nitrate. The present study demonstrates that the active PETN metabolite, PETriN, stimulates mRNA and protein expression as well as enzymatic activity of the antioxidant defense protein, HO-1, in endothelial cells. Increased HO-1 expression and ensuing formation of bilirubin and carbon monoxide may contribute to and explain the specific antioxidant and antiatherogenic actions of PETN.
Get full access to this article
View all access options for this article.
References
1.
Schröder H, Leitman DC, Bennett BM, Waldman SA, Murad F. Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther245:413–418, 1988.
2.
Harrison DG, Bates JN. The nitrovasodilators new ideas about old drugs. Circulation87:1461–1467, 1993.
3.
Feelisch M, Stamler JS. Donors of nitrogen oxides. In: Feelisch M, Stamler JS, Eds. Methods in Nitric Oxide Research. Chichester, NY: John Wiley & Sons Ltd, pp71–115, 1996.
4.
Crandall LA Jr, Leake CD, Loevenhart AS, Muehlberger CW. Acquired tolerance and cross tolerance between the nitrous and nitric acid and sodium nitrate in man. J Pharmacol Exp Ther41:103–120, 1931.
5.
Bogaert MG, De Schaepdryver AF. Tolerance towards glyceryl trinitrate (trinitrin) in dogs. Arch Int Pharmacodyn Ther171:221–224, 1968.
6.
Münzel T, Sayegh H, Freeman A, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. J Clin Invest95:187–194, 1995.
7.
Münzel T, Harrison DG. Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance. J Mol Med75:891–900, 1997.
8.
Fink B, Bassenge E. Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerythrityl tetranitrate. J Cardiovasc Pharmacol30:831–836, 1997.
9.
Dikalov S, Fink B, Skatchkov M, Stalleicken D, Bassenge E. Formation of reactive oxygen species by pentaerithrityltetranitrate and glyceryl trinitrate in vitro and development of nitrate tolerance. J Pharmacol Exp Ther286:938–944, 1998.
10.
Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, Parker JD. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: A human in vivo study. J Am Coll Cardiol38:854–859, 2001.
11.
Kojda G, Hacker A, Noack E. Effects of nonintermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and superoxide production. Eur J Pharmacol355:23–31, 1998.
12.
Kojda G, Stein D, Kottenberg E, Schnaith EM, Noack E. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol25:763–773, 1995.
13.
Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol271:C1424–C1437, 1996.
14.
Maines MD. The heme oxygenase system: A regulator of second messenger gases. Annu Rev Pharmacol Toxicol37:517–554, 1997.
15.
Immenschuh S, Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol60:1121–1128, 2000.
16.
Suttner DM, Sridhar K, Lee CS, Tomura T, Hansen TN, Dennery PA. Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells. Am J Physiol276:L443–L451, 1999.
17.
Yang L, Quan S, Abraham NG. Retrovirus-mediated HO gene transfer into endothelial cells protects against oxidant-induced injury. Am J Physiol277:L127–L133, 1999.
18.
Polte T, Abate A, Dennery PA, Schröder H. Heme oxygenase-1 is a cyclic GMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide. Arterioscler Thromb Vasc Biol20:1209–1215, 2000.
19.
Polte T, Hemmerle A, Grosser N, Abate A, Schröder H. Atrial natriuretic peptide reduces cyclosporin toxicity in renal cells: Role of cGMP and heme oxygenase-1. Free Radic Biol Med32:56–63, 2001.
20.
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science235:1043–1046, 1987.
21.
Coceani F. Carbon monoxide in vasoregulation. Circ Res86:1184–1186, 2000.
22.
Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA86:99–103, 1998.
23.
Suda K, Rothen-Rutishauser B, Gunthert M, Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: Endothelial versus epithelial features. In Vitro Cell Dev Biol Anim37:505–514, 2001.
24.
Oberle S, Schröder H. Ferritin may mediate SIN-1-induced protection against oxidative stress. Nitric Oxide1:308–314, 1997.
25.
Oberle S, Polte T, Abate A, Podhaisky H-P, Schröder H. Aspirin increases ferritin synthesis in endothelial cells: A novel antioxidant pathway. Circ Res82:1016–1020, 1998.
26.
Zhong H, Simons JW. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun259:523–526, 1999.
27.
Abate A, Yang G, Dennery PA, Oberle S, Schröder H. Synergistic inhibition of cyclooxygenase-2 by vitamin E and aspirin. Free Radic Biol Med29:1135–1142, 2000.
28.
Motterlini R, Foresti R, Intaglietta M, Winslow RM. NO-mediated activation of heme oxygenase: Endogenous cytoprotection against oxidative stress to endothelium. Am J Physiol270:H107–H114, 1996.
29.
Vreman HJ, Stevenson DK. Heme oxygenase activity as measured by carbon monoxide production. Anal Biochem168:31–38, 1988.
30.
Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods68:167–175, 1984.
31.
Hacker A, Muller S, Meyer W, Kojda G. The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br J Pharmacol132:1707–1714, 2001.
32.
Hinz B, Kuntze U, Schröder H. Pentaerithrityl tetranitrate and its phase I metabolites are potent activators of cellular cyclic GMP accumulation. Biochem Biophys Res Commun253:658–661, 1998.
33.
Crew MC, Gala RL, Haynes LJ, Di Carlo FJ. Biliary excretion and biotransformation of pentaerythritol trinitrate in rats. Biochem Pharmacol20:3077–3089, 1971.
34.
Weber W, Michaelis K, Luckow V, Kuntze U, Stalleicken D. Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites. Drug Res45:781–784, 1995.
35.
Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest103:129–135, 1999.
36.
Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol16:250–255, 1996.
37.
Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem46:1723–1727, 2000.
38.
Otterbein LE, Bach FH, Alam J, Soares M, Lu HT, Wysk M, Davis RJ, Flavell RA, Choi AMK. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med6:422–428, 2000.
39.
Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AMK, Soares MP. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med192:1015–1025, 2000.
40.
Oberle S, Schwartz P, Abate A, Schröder H. The antioxidant defense protein ferritin is a novel and specific target for pentaerithrityl tetranitrate. Biochem Biophys Res Commun261:28–34, 1999.
41.
Schröder H, Leitman DC, Hayward LD, Bennett BM, Murad F. Cultured rat lung fibroblasts as a model for organic nitrate-induced cyclic GMP accumulation and activation of guanylate cyclase. J Appl Cardiol2:301–311, 1987.
42.
Weber AA, Strobach H, Schrör K. Direct inhibition of platelet function by organic nitrates via nitric oxide formation. Eur J Pharmacol247:29–37, 1993.
43.
Abrams J. The role of nitrates in coronary heart disease. Arch Intern Med155:357–364, 1995.
